Evidence map›Paper›PMID 41930329›Full record

ArticleMedComm2026

Non-Viral Cytokine-Inducible SH2 Containing Protein Locus-Specific Integrated Fibroblast Activation Protein Alpha-Targeting Chimeric Antigen Receptor T Cells Achieve Potent Antitumor Efficacy in Glioblastoma.

Xin Dong, Yao Sun, Yuetong Guo, Jiao Wang, Fei Wang, Ziming Wang, Ruizhen Li, Fei Xie, Tingting Tan, Baijie Cheng and 8 more

Abstract read
In one paragraph

Article in MedComm, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Xin DongDepartment of Radiation Oncology Nanfang Hospital Southern Medical University Guangzhou Guangdong China.
Yao SunDepartment of Radiation Oncology Nanfang Hospital Southern Medical University Guangzhou Guangdong China.
Yuetong GuoDepartment of Radiation Oncology Nanfang Hospital Southern Medical University Guangzhou Guangdong China.
Jiao WangFull Circles Therapeutics Cambridge Massachusetts USA.
Fei WangDepartment of Radiation Oncology Nanfang Hospital Southern Medical University Guangzhou Guangdong China.
Ziming WangDepartment of Radiation Oncology Nanfang Hospital Southern Medical University Guangzhou Guangdong China.
Ruizhen LiDepartment of Radiation Oncology Nanfang Hospital Southern Medical University Guangzhou Guangdong China.
Fei XieNanfang PET Center Nanfang Hospital Southern Medical University Guangzhou Guangdong China.
Tingting TanDepartment of Radiation Oncology Nanfang Hospital Southern Medical University Guangzhou Guangdong China.
Baijie ChengDepartment of Pathology Guangdong Sanjiu Brain Hospital Guangzhou Guangdong China.
Ronghan HuangDepartment of Radiation Oncology Nanfang Hospital Southern Medical University Guangzhou Guangdong China.
Shu ZhangDepartment of Radiation Oncology Nanfang Hospital Southern Medical University Guangzhou Guangdong China.
Xiaotong LinDepartment of Radiation Oncology Nanfang Hospital Southern Medical University Guangzhou Guangdong China.
Zhaoze GuoBreast Center Department of General Surgery Nanfang Hospital Southern Medical University Guangzhou Guangdong China.
Hubing WuDepartment of Pathology Guangdong Sanjiu Brain Hospital Guangzhou Guangdong China.
Hao WuFull Circles Therapeutics Cambridge Massachusetts USA.
Xubiao ZhangDepartment of Neurosurgery Guangdong Sanjiu Brain Hospital Guangzhou Guangdong China.
Guozhu XieDepartment of Radiation Oncology Nanfang Hospital Southern Medical University Guangzhou Guangdong China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chimeric antigen receptor T (CAR-T) cells have been used to treat patients with glioblastoma (GBM) in clinical trial settings by targeting GBM-associated antigens. However, the efficacy of these CAR-T cells remains limited mainly due to the heterogeneous expression of tumor antigen and their anergy in the tumor microenvironment (TME). Cytokine-inducible SH2-containing protein (CIS, encoded by the gene

Indexed as

chimeric antigen receptor cell therapyclustered regularly interspaced short palindromic repeat/Cas9cytokine‐inducible SH2‐containing proteinfibroblast activation protein alphaglioblastoma

Identifiers

PMID41930329
PMCPMC13042763

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.